Literature DB >> 18326237

[Results of ADVANCE trial conducted in type 2 diabetic patients].

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18326237

Source DB:  PubMed          Journal:  Ter Arkh        ISSN： 0040-3660            Impact factor:   0.467


× No keyword cloud information.
  1 in total

1.  Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment.

Authors:  Hisazumi Araki; Yuki Tanaka; Syohei Yoshida; Yoshikata Morita; Shinji Kume; Keiji Isshiki; Shin-Ichi Araki; Takashi Uzu; Atsunori Kashiwagi; Hiroshi Maegawa
Journal:  J Diabetes Investig       Date:  2013-11-28       Impact factor: 4.232
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.